Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
If you decide to pursue this option, make sure you are working with a state-licensed compounding pharmacy or an FDA-registered outsourcing facility
The Associated Press contributed to this report.
I always advise my patients to decide exactly what they need to achieve in terms of their health and the timeframe for doing so, Dr
Here's the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
